Blancafort Jorquera, Adriana (Date of defense: 2016-01-29)
In this thesis,the association of FASN (fatty acid synthase) expression with clinicopathological and anthropometric characteristics in breast cancer patients is studied to find out FASN role as a ...
Palomeras, Sònia (Date of defense: 2019-02-27)
The major clinical problem for HER2+ breast cancer target therapies is the acquisition of resistance. The DNA methylation status of the promoter gene region has been described as a common epigenetic ...
Giró Perafita, Ariadna (Date of defense: 2017-01-17)
Triple-negative breast cancer (TNBC) represents 20% of breast cancer and patients receive only general chemotherapy. The epidermal growth factor receptor (EGFR) is commonly expressed in TNBC and it is ...
Rabionet Diaz, Marc (Date of defense: 2021-11-08)
Triple negative breast cancer (TNBC) accounts for 15-20% of the breast cancers and displays an aggressive profile, poor prognosis, high relapse risk and does not have a targeted therapy. In the last ...
Polonio Alcalá, Emma (Date of defense: 2023-05-17)
Although there are therapies for triple negative breast cancer (TNBC) and epidermal growth factor-mutated non-small cell lung cancer (EGFRm NSCLC), these two subtypes of cancer are very aggressive, and ...